Table 1.
Actual incidence rates and estimated rate differences for individuals without a family history between NHB and NHW women by age and breast cancer molecular subtype.
| NHB Incidence/100,000 | NHW Incidence/100,000 | Estimated incidence in NHB without family history (Per 100,000) | Estimated incidence in NHW without family history (Per 100,000) | Estimated Rate difference | |
|---|---|---|---|---|---|
| Overall | |||||
| TNBC | 38 | 19 | 31.2 | 12.5 | 18.7 |
| Luminal A (HR+, HER2−) | 112 | 138 | 94.1–96.9 | 107.1 | −13 to −10.2 |
| Luminal B (HR+, HER2+) | 21 | 20 | 17.6–18.2 | 15.5 | 2.1–2.7 |
| HER2+/enriched (HR−, HER2+) | 10 | 8 | 8.4–8.7 | 6.2 | 2.2–2.5 |
| <40 years | |||||
| TNBC | 9.7 | 5.7 | 8 | 3.8 | 4.2 |
| Luminal A | 17.8 | 17.9 | 15–15.4 | 13.9 | 1.1–1.5 |
| Luminal B | 6.7 | 6.6 | 5.6–5.8 | 5.1 | 0.5–0.7 |
| HER2+/enriched | 2.6 | 2.4 | 2.2 | 1.9 | 0.3 |
| 40–54 years | |||||
| TNBC | 34.6 | 17.5 | 28.4 | 11.6 | 16.8 |
| Luminal A | 84.4 | 113.3 | 70.9–73 | 87.9 | −17 to −14.9 |
| Luminal B | 19.9 | 20.4 | 16.7–17.2 | 15.8 | 0.9-1.4 |
| HER2+/enriched | 10.4 | 7.6 | 8.7–9 | 5.9 | 2.8–3.1 |
| 55–69 years | |||||
| TNBC | 52.6 | 25.1 | 43.1 | 16.6 | 26.5 |
| Luminal A | 164.3 | 207.9 | 138-142.1 | 161.3 | −23.3 to −19.2 |
| Luminal B | 30.3 | 27.1 | 25.5-26.2 | 21 | 4.5-5.2 |
| HER2+/enriched | 14.9 | 11.3 | 12.5-12.9 | 8.8 | 3.7-4.1 |
| 70–84 years | |||||
| TNBC | 49.6 | 27.8 | 43.1 | 16.6 | 22.4 |
| Luminal A | 214.1 | 268 | 138–142.1 | 161.3 | −28.2 to −22.8 |
| Luminal B | 25.4 | 25.3 | 25.5–26.2 | 21 | 1.7–2.4 |
| HER2+/enriched | 14.7 | 9.9 | 12.5–12.9 | 8.8 | 4.6-5 |